Intrabody therapy for SPG4 hereditary spastic paraplegia
Introducing a novel intrabody therapy for SPG4 hereditary spastic paraplegia, targeting the degradation of mutant M1 spastin protein. This approach aims to mitigate neurodegenerative symptoms by employing antibodies to d...